BIFIDOBACTERIUM LACTIS Bl-04®
Learn more about our premium strain for immune health
AIM OF THE STUDY
This study was designed to understand if daily intake of a formulation containing Bifidobacterium lactis Bl-04® would have a positive impact in the prevention of upper respiratory tract (URT) illness episodes
PRODUCT FORMULA
Bifidobacterium lactis Bl-04® 2 Billion CFU
STUDY DESIGN
5 month, double-blind, placebo-controlled study
Evaluation of symptoms & physical activity via Web-based questionnaire.
SUBJECTS
310 healthy physically active-adults, average age of 35 years
UNIVERSITY
Griffith Health Institute, Griffith University & Australian Institute of sport, Australia
PUBLICATION
West et al. 2014 Clinical Nutrition
AIM OF THE STUDY
To study the effect of Bifidobacterium lactis Bl-04® on immune response and rhinovirus load during rhinovirus infection that causes common cold.
PRODUCT FORMULA
Bifidobacterium lactis Bl-04® 2 Billion CFU
STUDY DESIGN
Randomized, double-blind, placebo controlled study.
SUBJECTS
115 healthy adults
OUTCOMES
Nasal immune response (IL-8), nasal rhinovirus load
UNIVERSITY
University of Virginia, USA; Prof. Ronald B Turner
PUBLICATION
Turner et al. Beneficial Microbes 2017
Strong clinical evidence from community-based study
- Results showed a significant decrease of 27% in the percentage of URTI episodes in the Bl-04® group vs placebo group (Kang et al., 2013)
- 0.7 month delay of median time for first respiratory infections compared to the plcebo group
- Robust long term study completed with a high number of subjects. (310 subjects / 5 months)
Unique evidence from the rhinovirus challenge study
- In the Bl-04® group, less virus was detected in the nasal washes compared to placebo during the infection
- Decreased proportion of subjects who had a detectable amount of virus
- A higher concentration of IL-8 after probiotic supplementation, prior to infection, indicating priming of the immune system
